Gastrointestinal stromal tumor

What is Gastrointestinal stromal tumor?

Gastrointestinal stromal tumor (GIST) is a rare type of cancer that develops in the digestive tract, most commonly in the stomach or small intestine. These tumors arise from specialized cells called interstitial cells of Cajal, which help control muscle contractions in the digestive system. GIST affects approximately 10-15 people per million each year, making it the most common type of sarcoma in the gastrointestinal tract but still considered a rare disease. While GIST can occur at any age, it most frequently affects adults between 50-70 years old.

Key statistics

Symptoms

Gastrointestinal bleeding, abdominal pain, feeling of fullness, nausea, vomiting, abdominal mass, fatigue, weight loss.

Many people with small GISTs experience no symptoms initially, which is why these tumors are often discovered incidentally during medical procedures for other conditions. The most common early symptom is gastrointestinal bleeding, which may be subtle and cause iron-deficiency anemia, or more obvious with black, tarry stools or vomiting blood. Abdominal pain and a feeling of early fullness during meals are also frequent complaints.

As tumors grow larger, patients may develop a palpable abdominal mass, persistent nausea and vomiting, and unintentional weight loss. Larger tumors can cause bowel obstruction, leading to severe abdominal pain, constipation, and inability to pass gas. Some patients experience fatigue and weakness due to chronic blood loss and anemia.

Submit Your Paper

Causes and risk factors

GIST is primarily caused by somatic mutations in two key genes: KIT (found in approximately 80% of cases) or PDGFRA (platelet-derived growth factor receptor alpha, found in 10-15% of cases). These mutations are typically acquired during a person’s lifetime rather than inherited, meaning they occur spontaneously in the tumor cells and are not passed down from parents.

The KIT and PDGFRA genes normally produce proteins that control cell growth and division. When these genes are mutated, they cause cells to grow and multiply uncontrollably, leading to tumor formation. A small percentage of GISTs (less than 5%) occur as part of hereditary syndromes, including neurofibromatosis type 1, Carney triad, or familial GIST syndrome.

Risk factors for developing GIST are not well established due to its rarity. Advanced age is the strongest known risk factor, with most cases occurring in people over 50. There is no clear association with diet, lifestyle factors, or environmental exposures.

Prevention

Currently, there are no established methods to prevent GIST, as the somatic mutations that cause most cases occur randomly and cannot be predicted or prevented. Since the vast majority of GISTs are not hereditary, routine genetic screening of the general population is not recommended.

For the rare families with hereditary GIST syndromes, genetic counseling and testing may be appropriate for family members. Individuals with neurofibromatosis type 1 should be monitored more closely, as they have an increased risk of developing GIST. Regular medical check-ups and prompt evaluation of gastrointestinal symptoms can help with early detection, though formal screening programs do not currently exist.

Complications

Without treatment, GIST can lead to serious complications. Local tumor growth may cause bowel obstruction, severe bleeding, or perforation of the intestinal wall, which can be life-threatening. The tumor may compress nearby organs, causing additional symptoms and dysfunction.

GIST has the potential to metastasize (spread) to other parts of the body, most commonly the liver and peritoneum (lining of the abdominal cavity). Metastatic disease significantly worsens the prognosis and makes treatment more challenging. Even after successful treatment, GIST can recur, particularly in cases with high-risk features such as large tumor size, high mitotic rate, or rupture during surgery.

Chronic bleeding from untreated GIST can lead to severe anemia, requiring blood transfusions and causing significant weakness and fatigue that impacts quality of life.

Diagnosis

Diagnosing GIST requires a combination of imaging studies, tissue sampling, and specialized testing. The diagnostic journey often begins with computed tomography (CT) scans or magnetic resonance imaging (MRI) when patients present with abdominal symptoms or bleeding.

Endoscopic procedures, including upper endoscopy or colonoscopy, may reveal the tumor if it’s accessible from the intestinal lumen. However, many GISTs grow outward from the intestinal wall and may not be visible during endoscopy.

The definitive diagnosis requires tissue biopsy, which can be obtained through endoscopic ultrasound-guided fine needle aspiration, CT-guided biopsy, or surgical sampling. Pathological examination reveals the characteristic spindle cell or epithelioid cell appearance of GIST.

Immunohistochemical staining is crucial for diagnosis, with most GISTs testing positive for the KIT protein (CD117) and DOG1 (discovered on GIST-1). Genetic testing of the tumor tissue identifies specific KIT or PDGFRA mutations, which is essential for treatment planning and determining the most appropriate targeted therapy.

Treatment

Treatment for GIST has been revolutionized by targeted therapies that specifically inhibit the mutated proteins driving tumor growth. The primary treatment approach depends on the tumor’s size, location, and genetic characteristics.

Surgery remains the cornerstone of treatment for localized, resectable GIST. Complete surgical removal with negative margins offers the best chance for cure. For tumors that are initially unresectable or would require extensive surgery, neoadjuvant targeted therapy may be used to shrink the tumor before surgical removal.

Imatinib is the first-line targeted therapy for most patients with advanced or metastatic GIST. This tyrosine kinase inhibitor effectively blocks the mutated KIT and PDGFRA proteins. For patients who develop resistance to imatinib, second-line options include sunitinib.

Third-line and beyond treatments include regorafenib and ripretinib, which can overcome various resistance mechanisms. For patients with specific PDGFRA mutations (particularly the D842V mutation), avapritinib has shown remarkable efficacy.

Adjuvant imatinib therapy is recommended for patients with high-risk GIST after complete surgical resection to reduce the risk of recurrence.

Prognosis

The prognosis for GIST has improved dramatically since the introduction of targeted therapies. Overall 5-year survival rates now exceed 85%, though outcomes vary significantly based on tumor characteristics and stage at diagnosis.

For patients with localized GIST that can be completely surgically removed, the prognosis is excellent, with many patients achieving long-term cure. The risk of recurrence depends on tumor size, mitotic rate, and location, with small gastric GISTs having the best prognosis.

For advanced or metastatic disease, targeted therapies have transformed GIST from a rapidly fatal condition to a chronic disease that can often be managed for many years. Median survival for patients with advanced GIST now exceeds 5-7 years with current treatments, and many patients live much longer with good quality of life.

Factors associated with better prognosis include smaller tumor size, low mitotic rate, gastric location, and presence of KIT mutations that respond well to imatinib. Regular monitoring and prompt treatment of disease progression help optimize long-term outcomes.

Quality of life

Most patients with GIST can maintain good quality of life, especially those with localized disease treated with surgery alone. For patients requiring long-term targeted therapy, side effects are generally manageable and improve over time as the body adjusts to treatment.

Common side effects of targeted therapies include fatigue, diarrhea, skin changes, and fluid retention. These can usually be managed with supportive medications and dose adjustments when necessary. Many patients are able to continue working and participating in normal activities while on treatment.

Regular exercise, when tolerated, can help manage fatigue and maintain strength. A balanced diet rich in nutrients supports overall health, though specific dietary restrictions are typically not necessary. Patients should stay well-hydrated and may need to avoid certain foods that worsen diarrhea.

Mental health support is important, as dealing with a cancer diagnosis can cause anxiety and depression. Many patients benefit from counseling, support groups, or connecting with other GIST patients through advocacy organizations.

Pregnancy and fertility

GIST primarily affects older adults, so pregnancy considerations are less common but still important. The targeted therapies used to treat GIST can potentially harm a developing fetus, so effective contraception is essential for patients of childbearing age receiving treatment.

For women who become pregnant while having GIST, treatment decisions require careful coordination between oncologists and high-risk pregnancy specialists. In some cases, treatment may need to be delayed or modified during pregnancy, particularly during the first trimester when organ development occurs.

Male patients receiving targeted therapy may experience temporary effects on fertility, though this typically reverses after treatment completion. Patients planning to have children should discuss fertility preservation options with their healthcare team before starting treatment.

Genetic counseling is recommended for the rare patients with hereditary GIST syndromes, as these conditions can be passed to children.

Children

GIST is extremely rare in children and adolescents, representing less than 1% of all cases. Pediatric GIST often has different characteristics compared to adult disease, including a higher likelihood of wild-type tumors (lacking KIT or PDGFRA mutations) and different response patterns to treatment.

Young patients, particularly females, may develop GIST as part of Carney triad, which also includes pulmonary chondromas and paragangliomas. These cases typically don’t respond as well to standard targeted therapies and may require different treatment approaches.

Treatment of pediatric GIST requires specialized expertise and should be managed at centers with experience in both pediatric oncology and GIST. Clinical trials specifically designed for young patients may offer access to newer treatments.

When to see a doctor

Seek immediate medical attention for severe abdominal pain, vomiting blood, black or bloody stools, signs of bowel obstruction (inability to pass gas or stool with severe cramping), or symptoms of severe anemia such as extreme fatigue, dizziness, or rapid heartbeat.

Schedule routine medical evaluation for persistent abdominal pain, unexplained weight loss, early satiety, or chronic fatigue. While these symptoms have many possible causes, early evaluation can lead to prompt diagnosis if GIST is present.

For patients already diagnosed with GIST, regular follow-up appointments are essential for monitoring treatment response and detecting any signs of disease progression or treatment-related side effects.

Regional context

Limited data exists specifically regarding GIST prevalence in the Caucasus region (Georgia, Armenia, Azerbaijan) and Eastern Mediterranean countries. The global incidence of 10-15 cases per million people annually likely applies to these regions, though local cancer registries may not capture all cases due to diagnostic challenges and healthcare access variations.

Healthcare providers in these regions may benefit from increased awareness of GIST to improve diagnosis and ensure patients have access to appropriate targeted therapies. The Global Medical Journal welcomes contributions from regional specialists to better understand GIST patterns and treatment access in these areas.

Research and clinical trials

GIST research continues to advance rapidly, focusing on overcoming drug resistance, developing new targeted therapies, and understanding tumor biology. Current research areas include combination therapies, immunotherapy approaches, and treatments for specific molecular subtypes.

Several promising new drugs are in clinical development, including next-generation tyrosine kinase inhibitors and novel therapeutic targets. Research into the tumor microenvironment and immune system interactions may lead to new immunotherapy options.

Patients interested in clinical trials can search for opportunities at ClinicalTrials.gov, using search terms like “GIST,” “gastrointestinal stromal tumor,” or specific drug names. Participation in clinical trials not only provides access to cutting-edge treatments but also contributes to advancing care for all GIST patients.

Frequently asked questions

Is GIST hereditary?

The vast majority of GISTs (over 95%) are not hereditary and occur due to spontaneous mutations. Only a small percentage are associated with inherited syndromes like familial GIST or neurofibromatosis type 1.

How long do I need to take targeted therapy?

For advanced GIST, targeted therapy is typically continued indefinitely as long as it’s controlling the disease and side effects are manageable. Stopping treatment usually leads to rapid disease progression.

Can GIST be cured?

Yes, GIST can be cured if caught early and completely removed with surgery. For advanced disease, cure is less common, but many patients live for many years with good quality of life on targeted therapies.

What happens if my GIST becomes resistant to treatment?

If resistance develops, your oncologist will typically switch to a different targeted therapy. Several options are available, and new treatments continue to be developed for resistant disease.

Are there dietary restrictions with GIST treatment?

Most patients don’t need special diets, though some may need to avoid foods that worsen treatment side effects like diarrhea. Staying well-hydrated and maintaining good nutrition is important.

Support and resources

GIST Support International – Primary patient advocacy organization providing education, support, and research funding
Website: www.gistsupport.org

National Organization for Rare Disorders (NORD)
Website: www.rarediseases.org

Orphanet – International reference portal for rare diseases
Website: www.orpha.net

EURORDIS – Rare Diseases Europe
Website: www.eurordis.org

Sarcoma Alliance
Website: www.sarcomaalliance.org

Related conditions

Leiomyosarcoma
Neurofibromatosis type 1
Carney complex
Gastric adenocarcinoma
Small bowel adenocarcinoma

Sources: Orphanet (orpha.net), OMIM, GeneReviews (NCBI), WHO ICD-11, relevant guidelines. Informational only; not medical advice. CC BY 4.0.

Licensed under CC BY 4.0. Free to share with attribution to GMJ News.

Sources: Orphanet (orpha.net), OMIM, GeneReviews (NCBI), WHO ICD-11, EULAR/ACR guidelines. Schema.org MedicalCondition structured data included.